Dare Bioscience Investor Presentation Deck slide image

Dare Bioscience Investor Presentation Deck

Ovaprene® Investigational Hormone-Free, Monthly Contraceptive Physical Barrier 6 Three-dimensional, knitted polymer barrier Spermiostatic Environment Contraceptive-loaded silicone ring releasing non-hormonal active Ferrous gluconate Desired Features of Birth Control Products:¹-4 +Efficacy +Hormone Free +Convenience +Favorable Side Effect Profile + Easily Manage Fertility Design Features of Ovaprene: 5-7 86% - 91% Expected Typical Use Effectiveness Approaching User-Controlled Hormone Contraception No Hormones in the API Unique dual action MOA (spermiostatic & barrier) Monthly Ring Form Women choose monthly intravaginal products for the convenience of a non-daily option Safety Profile Similar to a Diaphragm No significant changes in vaginal flora and no serious adverse effects observed in studies to date No Systemic/Long-term Activity Inserted and removed without a provider allowing for immediate return to fertility 1.https://www.urban.org/urban-wire/women-want-effective-birth-control 2.Lessard, L, Perspectives on Sexual and Reproductive Health, Volume 44, Number 3,9-2012 3.Hooper, DJ, Clin Drug Investig. 2010;30(11):74963 4.Ersek, J, Matern Child Health J (2011) 15:497-506 5.In PCT studies of similarsize, products (diaphragms) that demonstrated no motile sperm in the cervical mucus during PCT assessments later demonstrated "typical use" contraceptive effectiveness of 86-91% in pivotal contraceptive studies evaluating pregnancy rates over six-month periods. Mauck C, Vincent K. Biology of Reproduction, Volume 103, Issue 2, August 2020, Pages 437-444 6. Journal of Reproductive Medicine 2009; 54: 685-690 7. Trussell J. Contraceptive Efficacy. In Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar M. Contraceptive Technology: Twentieth Revised Edition. New York, NY: Ardent Media, 2011. 26
View entire presentation